


Claims

[Claim 1]

A crystal of an oxazole compound represented by formula (5)



wherein the crystal has peaks at diffraction angles $2\theta(^{\circ})$ of 9.6 ± 0.2 , 19.1 ± 0.2 , and 21.2 ± 0.2 in an X-ray powder diffraction pattern measured using $\text{CuK}\alpha$ characteristic X-rays.

[Claim 2]


The crystal according to claim 1, wherein the crystal further has one, two, or three peaks at one, two, or three diffraction angles $2\theta(^{\circ})$ selected from the group consisting of 12.6 ± 0.2 , 22.8 ± 0.2 , and 26.0 ± 0.2 in the X-ray powder diffraction pattern measured using $\text{CuK}\alpha$ characteristic X-rays.

[Claim 3]

The crystal according to claim 2, wherein the crystal further has one or more peaks at one or more diffraction angles $2\theta(^{\circ})$ selected from the group consisting of 10.4 ± 0.2 , 11.9 ± 0.2 , 15.0 ± 0.2 , 15.9 ± 0.2 , 19.7 ± 0.2 , 24.7 ± 0.2 , and 27.6 ± 0.2 in the X-ray powder diffraction pattern measured using $\text{CuK}\alpha$ characteristic X-rays.

[Claim 4]

A crystal of an oxazole compound represented by formula (5)



wherein the crystal has infrared absorption bands at wavenumbers (cm^{-1}) of 3380 ± 5 , 2980 ± 5 , 1651 ± 2 , 1501 ± 2 , 1258 ± 2 , 1121 ± 2 , and 754 ± 2 in an infrared absorption spectrum measured by a potassium bromide disk method.

[Claim 5]


The crystal according to any one of claims 1 to 3, wherein the crystal has infrared absorption bands at wavenumbers (cm^{-1}) of 3380 ± 5 , 2980 ± 5 , 1651 ± 2 , 1501 ± 2 , 1258 ± 2 , 1121 ± 2 , and 754 ± 2 in an infrared absorption spectrum measured by a potassium bromide disk method.

[Claim 6]

The crystal according to claim 4 or 5, wherein the crystal further has one or more infrared absorption bands at one or more wavenumbers (cm^{-1}) selected from the group consisting of 1601 ± 2 , 1537 ± 2 , 1302 ± 2 , 1234 ± 2 , 1107 ± 2 , 1026 ± 2 , and 627 ± 2 in the infrared absorption spectrum measured by the potassium bromide disk method.

[Claim 7] The crystal according to any one of claims 1 to 6, wherein the crystal has a melting point of 75 to 90°C.

[Claim 8] A crystal of an oxazole compound represented by formula (5)



wherein the crystal has a melting point of 75 to 90°C.

[Claim 9] A pharmaceutical composition comprising the crystal according to any one of claims 1 to 8.

[Claim 10] The pharmaceutical composition according to claim 9, for use in the treatment and/or prevention of eczema or dermatitis.

[Claim 11] The pharmaceutical composition according to claim 9 or 10, which is an ointment.